 BLA filing of SRP-9001 for the treatment of patients with DMD is expected in fall of 2022; If filing and review go well then FDA Accelerated approval possible mid-2023. The global market opportunity for Duchenne Muscular Dystrophy is expected to reach 4.11 billion by 2023. 